Amneal Q2 Net Revenue $796.2M, Net Income $57.7M; New Deals Signed
Amneal Pharmaceuticals reported strong second-quarter 2026 results with net revenue increasing to $796.2 million and net income attributable to the company rising to $57.7 million. The company also announced several strategic agreements, including an exclusive distribution deal for generic mirabegron with MSN Laboratories, a license and supply agreement with Adalvo for two generic tirzepatide products, and a supply agreement with mAbxience for denosumab biosimilars. Additionally, an update to the Pfizer collaboration resulted in a $6.9 million gain.
Key Highlights
- Q2 2026 Net Revenue increased 9.9% to $796.2 million from $724.5 million in Q2 2025.
- Q2 2026 Net Income attributable to Amneal Pharmaceuticals rose 157.6% to $57.7 million from $22.4 million in Q2 2025.
- Q2 2026 Diluted EPS was $0.18, up from $0.07 in Q2 2025.
- Entered exclusive distribution agreement with MSN Laboratories for generic mirabegron, with a $75.0 million upfront payment.
- Signed License and Supply Agreement with Adalvo for two generic tirzepatide products, with up to $21.0 million in milestone payments.
- Executed supply agreement with mAbxience for denosumab biosimilars, including a $6.0 million signing fee.
- Recognized a $6.9 million gain from the Pfizer collaboration agreement update.
- Net cash used in operating activities for H1 2026 was $(48.0) million, compared to $91.2 million provided in H1 2025.
Price Impact
More from AMRX
Amneal Pharmaceuticals Acquires Kashiv BioSciences for $1.3B; Q3 Revenue $863M, Net Loss $(21.7)M
Amneal Pharmaceuticals Q3 Revenue $863M; Raises 2026 Guidance
Amneal Completes Kashiv BioSciences Acquisition for $375M Cash